Microalbuminuria as a target to improve cardiovascular and renal outcomes in diabetic patients

Yokoyama H, Kawai K, Kobayashi M: Microalbuminuria is common in Japanese type 2 diabetic patients. Diabetes Care 2007, 30:989–992. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–890. Anavekar NS, Gans DJ, Berl T, et al.: Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int 2004, 66:S50–S55. de Zeeuw D, Remuzzi G, Parving HH, et al.: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921–927. Gerstein HC, Mann JFE, Yi Q, et al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421–426. Araki S, Haneda M, Koya D, et al.: Reduction in micro-albuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 2007, 56:1727–1730. American Diabetes Association: Standards of medical care. Diabetes Care 2005, 28Suppl 1):S4–S36. Arnlov J, Evans J, Meigs J, et al.: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals, the Framingham heart study. Circulation 2005, 112:969–975. Comper WD, Osicka TM: Albumin-like material in urine. Kidney Int Suppl 2004, 92:S65–S66. Rao PV, Lu X, Standley M, et al.: Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007, 30:629–637. Otu HH, Can H, Spentzos D, et al.: Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007, 30:638–643. Schmieder RE, Delles C, Mimran A, et al.: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007, 30:1351–1356. Tamsma JT, van den Born J, Bruijn JA, et al.: Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulfate in the glomerular basement membrane. Diabetologia 1994, 37:313–320. Van der Pijl JW, Daha MR, Van Den Born J, et al.: Extracellular matrix in human diabetic nephropathy: reduced expression of heparan sulfate in skin basement membrane. Diabetologia 1998, 41:791–798. Gambaro G, Kinalska I, Oksa A, et al.: Oral sulodexide reduced albuminuria in microalbuminuric and macroalbuminuria type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002, 13:1615–1625. Gambaro G, Cavazzana AO, Luzi P, et al.: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992, 42:285–291. Yokokawa K, Kohno M, Mandal AK, et al.: Heparin suppresses endothelin-1 (ET-1) peptide and mRNA expression in cultured endothelial cells of spontaneously hypertensive rats. J Am Soc Nephrol 1994, 4:1683–1689. Reantragoon S, Arrigo LM, Seoud MA, et al.: Specific heparin fractions suppress ET-1 production in cultured human umbilical vein endothelial cells. Arch Biochem Biophys 1994, 314:315–322. Ceol M, Vianello D, Schleicher E, et al.: Heparin reduces glomerular infiltration and TGF-beta protein expression by macrophages in puromycin glomerulosclerosis. J Nephrol 2003, 16:210–218. Sulikowska B, Olejniczak H, Muszynska M, et al.: Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrology 2006, 26:621–628. Fogari R, Derosa G, Zoppi A, et al.: Effect of telmisartanamlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 2007, 20:417–422. Shiga Microalbuminuria Reduction Trial (SMART) Group: Reduction of microalbuminuria in patients with type 2 diabetes. Diabetes Care 2007, 30:1581–1583. Bakris GL, Ruilope LM, McMorn SO, et al.: Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertension 2006, 24:2047–2055. Lazarevic G, Antic S, Vlahovic P, et al.: Effects of aerobic exercise on microalbuminuria and enzymuria in type 2 diabetic patients. Renal Failure 2007, 29:199–205. Saito K, Sone H, Kawai K, et al.: Risk imparted by various parameters of smoking in Japanese men with type 2 diabetes on their development of microalbuminuria. Diabetes Care 2007, 30:1286–1288.